Search

Butorphanol

A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.

Fexofenadine

[L4269] It is selective for the H₁ receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier[L10779] - this is in contrast to previous first-generation … antihistamines, such as [diphenhydramine], which readily bind to off-targets that contribute to side effects such as sedation.

Dichlorobenzyl alcohol

[L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773] … [A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical.

Valproate bismuth

Valproate bismuth is available in Canada in the over-the-counter medication Neo-Laryngobis.

Pindolol

Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. … [L32353] Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia.

5-[(3R)-3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine

Methyldopa

Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. … Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].

Sulindac

While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2. … Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes.

Citalopram

[A261316] Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.[L5230] … [A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors.